id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-E-0061-0008,FDA,FDA-2003-E-0061,"Certificate Extending Patent Term from U.S. Patent and Trademark Office from Merck & Co., Inc.",Rule,Certificate Extending Patent Term,2007-03-15T04:00:00Z,2007,3,,,2025-10-24T19:22:04Z,,0,0,0900006480481af1
FDA-2003-E-0061-0006,FDA,FDA-2003-E-0061,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-05-24T04:00:00Z,2006,5,,,2025-10-24T19:17:48Z,,0,0,0900006480481aef
FDA-2003-E-0061-0007,FDA,FDA-2003-E-0061,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-05-24T04:00:00Z,2006,5,,,2025-10-24T19:20:18Z,,0,0,0900006480481af0
FDA-2003-E-0061-0005,FDA,FDA-2003-E-0061,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2004-06-28T04:00:00Z,2004,6,,,2025-10-24T19:15:27Z,,0,0,0900006480481aee
FDA-2003-E-0061-0004,FDA,FDA-2003-E-0061,Determination of Regulatory Review Period for Purposes of Patent Extension; INVANZ,Notice,General Notice,2003-12-02T05:00:00Z,2003,12,2003-12-02T05:00:00Z,,2025-10-24T19:12:22Z,03-29929,0,0,0900006480481aed
FDA-2003-E-0061-0003,FDA,FDA-2003-E-0061,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2003-11-12T05:00:00Z,2003,11,,,2025-10-24T19:08:44Z,,0,0,0900006480481aec
FDA-2003-E-0061-0002,FDA,FDA-2003-E-0061,Letter from U S Patent and Trademark Office to FDA CDER,Other,Letter(s),2003-10-06T04:00:00Z,2003,10,,,2025-10-24T19:00:48Z,,0,0,0900006480481aeb
FDA-2003-E-0061-0001,FDA,FDA-2003-E-0061,Letter from U S Patent and Trademark Office to FDA CDER,Other,Letter(s),2003-06-06T04:00:00Z,2003,6,,,2025-10-24T18:53:57Z,,0,0,0900006480481ae8